G1 Therapeutics Inc. (NASDAQ: GTHX) kicked off on May 23, 2023, at the price of $2.865, up 0.69% from the previous trading day. During the day, the shares moved up to $3.07 and dropped to $2.83 before settling in for the closing price of $2.88. Over the past 52 weeks, GTHX has traded in a range of $2.38-$17.49.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 4.40%. With a float of $46.71 million, this company’s outstanding shares have now reached $51.65 million.
The extent of productivity of a business whose workforce counts for 170 workers is very important to gauge. In terms of profitability, gross margin is +92.69, operating margin of -265.45, and the pretax margin is -284.32.
G1 Therapeutics Inc. (GTHX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of G1 Therapeutics Inc. is 0.90%, while institutional ownership is 51.30%. The most recent insider transaction that took place on Jan 05, was worth 3,942. In this transaction Chief Medical Officer of this company sold 729 shares at a rate of $5.41, taking the stock ownership to the 102,739 shares. Before that another transaction happened on Jan 05, when Company’s General Counsel sold 729 for $5.41, making the entire transaction worth $3,942. This insider now owns 41,087 shares in total.
G1 Therapeutics Inc. (GTHX) Latest Financial update
In the latest quarterly report, which was put into the public domain on 3/30/2023, the organization reported -$0.53 earnings per share (EPS), higher than consensus estimate (set at -$0.64) by $0.11. This company achieved a net margin of -287.63 while generating a return on equity of -139.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.40% per share during the next fiscal year.
G1 Therapeutics Inc. (NASDAQ: GTHX) Trading Performance Indicators
Take a look at G1 Therapeutics Inc.’s (GTHX) current performance indicators. Last quarter, stock had a quick ratio of 4.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.77, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -1.11 in one year’s time.
Technical Analysis of G1 Therapeutics Inc. (GTHX)
The latest stats from [G1 Therapeutics Inc., GTHX] show that its last 5-days average volume of 0.74 million was inferior to 1.13 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 49.08%. Additionally, its Average True Range was 0.22.
During the past 100 days, G1 Therapeutics Inc.’s (GTHX) raw stochastic average was set at 8.64%, which indicates a significant decrease from 44.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.57% in the past 14 days, which was lower than the 140.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.80, while its 200-day Moving Average is $7.30. Now, the first resistance to watch is $3.04. This is followed by the second major resistance level at $3.17. The third major resistance level sits at $3.28. If the price goes on to break the first support level at $2.80, it is likely to go to the next support level at $2.69. The third support level lies at $2.56 if the price breaches the second support level.
G1 Therapeutics Inc. (NASDAQ: GTHX) Key Stats
The company with the Market Capitalisation of 145.61 million has total of 51,661K Shares Outstanding. Its annual sales at the moment are 51,300 K in contrast with the sum of -147,560 K annual income. Company’s last quarter sales were recorded 12,950 K and last quarter income was -27,600 K.
